Federal Circuit affirms preemption of D.C.’s Prescription Drug Excessive Pricing Act of 2005 In a recent decision, the Federal Circuit affirmed the District Court for the District of Columbia's judgment that the federal patent laws preempted the District of Columbia's Prescription Drug Excessive Pricing Act of 2005. More details of Biotechnology Indus. Org. v. District of Columbia after the jump. The challenged legislation at issue is the Excessive […] Continue Reading →
Revised TTAB rules published, some take effect August 31, others November 1 As noted last week, the revised TTAB rules were published in today's Federal Register. The final rules are somewhat different than those proposed last January. Some of the new rules include: Opposers/Petitioners will serve copies of the notice of opposition or cancellation petition on the opposing party directly, rather than having the TTAB send out […] Continue Reading →